Jaime R. Merchan
About
Jaime R. Merchan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Jaime R. Merchan has authored 140 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 41 papers in Cancer Research. Recurrent topics in Jaime R. Merchan's work include Renal cell carcinoma treatment (33 papers), Pancreatic and Hepatic Oncology Research (22 papers) and Virus-based gene therapy research (22 papers). Jaime R. Merchan is often cited by papers focused on Renal cell carcinoma treatment (33 papers), Pancreatic and Hepatic Oncology Research (22 papers) and Virus-based gene therapy research (22 papers). Jaime R. Merchan collaborates with scholars based in United States, Australia and Canada. Jaime R. Merchan's co-authors include Vikas P. Sukhatme, S. Ananth Karumanchi, James P. Morgan, Frank W. Sellke, Sharon E. Maynard, Jianyi Li, Isaac E. Stillman, Franklin H. Epstein, Susanta Mondal and Towia A. Libermann and has published in prestigious journals such as JAMA, Journal of Clinical Investigation and Journal of Clinical Oncology.
In The Last Decade
Jaime R. Merchan
133 papers receiving 7.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jaime R. Merchan United States | 31 | 2.9k | 2.3k | 2.1k | 2.1k | 1.9k | 140 | 7.4k | ||
| Sven� Mahner Germany | 41 | 1.7k 0.6× | 1.5k 0.7× | 685 0.3× | 189 0.1× | 1.6k 0.8× | 337 | 6.2k | ||
| Gilad Ben‐Baruch Israel | 39 | 1.3k 0.4× | 1.4k 0.6× | 281 0.1× | 390 0.2× | 995 0.5× | 152 | 4.7k | ||
| A. Ayhan Türkiye | 40 | 1.2k 0.4× | 1.7k 0.8× | 683 0.3× | 120 0.1× | 1.2k 0.6× | 224 | 5.3k | ||
| Franco Odicino Italy | 33 | 4.0k 1.4× | 1.0k 0.4× | 583 0.3× | 116 0.1× | 1.3k 0.7× | 128 | 6.7k | ||
| Bertrand Knebelmann France | 46 | 162 0.1× | 3.0k 1.3× | 1.0k 0.5× | 520 0.3× | 519 0.3× | 123 | 6.2k | ||
| Francisco España Spain | 42 | 718 0.3× | 768 0.3× | 890 0.4× | 130 0.1× | 212 0.1× | 177 | 5.2k | ||
| Charles C. Guo United States | 38 | 255 0.1× | 1.6k 0.7× | 2.0k 1.0× | 178 0.1× | 986 0.5× | 136 | 5.4k | ||
| Tae‐Joong Kim South Korea | 40 | 2.2k 0.8× | 1.2k 0.5× | 424 0.2× | 58 0.0× | 817 0.4× | 243 | 5.2k | ||
| George D. Demetri United States | 32 | 187 0.1× | 1.3k 0.6× | 2.0k 0.9× | 167 0.1× | 1.8k 0.9× | 104 | 5.0k | ||
| Toru Nakanishi Japan | 34 | 1.6k 0.6× | 1.1k 0.5× | 695 0.3× | 76 0.0× | 682 0.4× | 148 | 4.3k |
Countries citing papers authored by Jaime R. Merchan
Since
Specialization
Citations
This map shows the geographic impact of Jaime R. Merchan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaime R. Merchan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaime R. Merchan more than expected).
Fields of papers citing papers by Jaime R. Merchan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jaime R. Merchan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaime R. Merchan. The network helps show where Jaime R. Merchan may publish in the future.
Co-authorship network of co-authors of Jaime R. Merchan
This figure shows the co-authorship network connecting the top 25 collaborators of Jaime R. Merchan. A scholar is included among the top collaborators of Jaime R. Merchan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaime R. Merchan. Jaime R. Merchan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2025). Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(5_suppl). 549–549.
2.
Choueiri, Toni K., Jae‐Lyun Lee, Jaime R. Merchan, et al.. (2025). Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.. Journal of Clinical Oncology. 43(5_suppl). 441–441.
3.
Chauhan, Aman, Isildinha M. Reis, Chinmay Jani, et al.. (2025). 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. Annals of Oncology. 36. S954–S954.
4.
Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. Journal of Clinical Oncology. 42(16_suppl). 4504–4504.
5.
Jonasch, Eric, Todd M. Bauer, Kyriakos P. Papadopoulos, et al.. (2023). Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. European Journal of Cancer. 196. 113434–113434.
6.
Jones, Sandra C., et al.. (2023). Epidemiologic and socioeconomic characteristics of Hispanics diagnosed with metastatic renal cell carcinoma in the US.. Journal of Clinical Oncology. 41(16_suppl). e16555–e16555.
7.
Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2023). LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology. 34. S1328–S1329.
8.
Curran, Catherine, Elio Adib, Petros Grivas, et al.. (2021). Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. Clinical Genitourinary Cancer. 20(1). 11–16.
9.
Azaro, Analía, Christophe Massard, William D. Tap, et al.. (2021). A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Investigational New Drugs. 39(4). 1089–1098.
10.
Wilky, Breelyn A., Matteo Trucco, Ty K. Subhawong, et al.. (2019). Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. The Lancet Oncology. 20(6). 837–848.
11.
Middleton, Mark R., Joseph J. Sacco, Jaime R. Merchan, et al.. (2019). Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors. Journal for ImmunoTherapy of Cancer. 7.
12.
Ban, Yuguang, et al.. (2017). Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer. Molecular Cancer Research. 15(10). 1410–1420.
13.
Montero, Alberto J., Deukwoo Kwon, Jonathan C. Trent, et al.. (2016). A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(13). 3209–3217.
14.
Decatur, Christina L., et al.. (2015). 2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation. Molecular Cancer Therapeutics. 15(2). 264–275.
15.
Kurisetty, Vittal, et al.. (2012). Role of Plasminogen Activator Inhibitor-1 in Urokinase's Paradoxical In Vivo Tumor Suppressing or Promoting Effects. Molecular Cancer Research. 10(10). 1271–1281.
16.
Merchan, Jaime R., Jessica MacIntyre, Kristen K. Ciombor, et al.. (2011). Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer. American Journal of Clinical Oncology. 35(5). 446–450.
17.
Bhatt, Rupal S., Jaime R. Merchan, Robert Parker, et al.. (2010). A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 116(7). 1751–1756.
18.
Merchan, Jaime R., Metin Kurtoğlu, Yolanda Piña, et al.. (2010). Antiangiogenic Activity of 2-Deoxy-D-Glucose. PLoS ONE. 5(10). e13699–e13699.
19.
Tong, Caili, Jin Zhang, Takafumi Nakamura, et al.. (2009). Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor. Cancer Research. 69(4). 1459–1468.
20.
Huang, Guosheng, Rosana Eisenberg, Min Yan, et al.. (2008). 15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3β and a Tumor Suppressor in Lung Cancer. Cancer Research. 68(13). 5040–5048.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sven� Mahner Breakdown of academic impact, for papers by Gilad Ben‐Baruch Breakdown of academic impact, for papers by A. Ayhan Breakdown of academic impact, for papers by Franco Odicino Breakdown of academic impact, for papers by Bertrand Knebelmann Breakdown of academic impact, for papers by Francisco España Breakdown of academic impact, for papers by Charles C. Guo Breakdown of academic impact, for papers by Tae‐Joong Kim Breakdown of academic impact, for papers by George D. Demetri Breakdown of academic impact, for papers by Toru Nakanishi